{"id":176582,"date":"2019-05-02T00:00:00","date_gmt":"2019-05-01T22:00:00","guid":{"rendered":"https:\/\/www.bcfi.be\/alemtuzumab-beperking-van-het-gebruik-om-veiligheidsredenen\/"},"modified":"2026-04-02T19:10:47","modified_gmt":"2026-04-02T17:10:47","slug":"alemtuzumab-beperking-van-het-gebruik-om-veiligheidsredenen","status":"publish","type":"post","link":"https:\/\/h.cbip.be\/nl\/alemtuzumab-beperking-van-het-gebruik-om-veiligheidsredenen\/","title":{"rendered":"Alemtuzumab &#8211; Beperking van het gebruik om veiligheidsredenen"},"content":{"rendered":"<p>Naar aanleiding van nieuwe ongewenste effecten&#x002C; heeft het Europees Geneesmiddelenbureau (EMA) een herziening van de risico-batenverhouding van <a href='https:\/\/www.bcfi.be\/nl\/chapters\/13?frag=21063'>alemtuzumab<\/a> (Lemtrada\u00ae) voor de behandeling van multipele sclerose opgestart. Het gaat om cardiovasculaire bijwerkingen (met ook fatale gevallen) en immuungemedieerde bijwerkingen (auto-immuun hepatitis en hemofagocytaire lymfohistiocytose). Meer informatie is beschikbaar via de <a href='https:\/\/www.fagg.be\/sites\/default\/files\/content\/dhpc_lemtrada_nl_-_website.pdf'>rechtstreekse mededeling aan de gezondheidszorgbeoefenaars<\/a> (Direct Healthcare Professional Communication &#8211; DHPC).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Naar aanleiding van nieuwe ongewenste effecten&#x002C; heeft het Europees Geneesmiddelenbureau  [&#8230;]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[43,66],"tags":[20213,20224],"class_list":["post-176582","post","type-post","status-publish","format-standard","hentry","category-nieuw","category-2019-nl","tag-import_tags","tag-import_tags-nl"],"_links":{"self":[{"href":"https:\/\/h.cbip.be\/nl\/wp-json\/wp\/v2\/posts\/176582","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/h.cbip.be\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/h.cbip.be\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/h.cbip.be\/nl\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/h.cbip.be\/nl\/wp-json\/wp\/v2\/comments?post=176582"}],"version-history":[{"count":1,"href":"https:\/\/h.cbip.be\/nl\/wp-json\/wp\/v2\/posts\/176582\/revisions"}],"predecessor-version":[{"id":179160,"href":"https:\/\/h.cbip.be\/nl\/wp-json\/wp\/v2\/posts\/176582\/revisions\/179160"}],"wp:attachment":[{"href":"https:\/\/h.cbip.be\/nl\/wp-json\/wp\/v2\/media?parent=176582"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/h.cbip.be\/nl\/wp-json\/wp\/v2\/categories?post=176582"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/h.cbip.be\/nl\/wp-json\/wp\/v2\/tags?post=176582"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}